Vibose 200 mcg (Tablet)

Title and Category

• Vibose tablets
• Diabetes medication
• Oral hypoglycemic agents
• Alpha-glucosidase inhibitor

Usage

• Reduction in Post-Prandial Hyperglycaemia (PPHG)
• Immunotherapy for non-insulin-dependent diabetes mellitus (NIDDM)
• Combination therapy with other OHAs
• Prevention of onset of type 2 diabetes mellitus in impaired glucose tolerance
• Prevention of hypoglycaemia in glycogen storage disease
• Prevention of hypoglycaemic attacks in non-diabetic Hyperinsulinemia
• Prevention of hypoglycaemia in steroid-induced diabetes mellitus

Description

• Selective inhibition of α-glucosidase in the enteric canal
• Suppression of sharp increase in post-prandial plasma glucose

Pharmacology

• Inhibition of enzymes needed to digest carbohydrates
• Reduction in the rate of digestion of complex carbohydrates
• Reduction in glucose absorption
• Decrease in current blood glucose levels
• Small reduction in hemoglobin-A1c level

Dosage and Administration

• Oral administration in a single dose of 0.2 mg, 3 times a day
• Possible dose adjustment to 0.3 mg if necessary
• Lower starting dose for elderly patients
• Close observation for geriatrics

Interaction

• Cautious administration with antidiabetic drugs
• Enhancement or diminishment of hypoglycaemic action by concomitant drugs

Contraindications

• Hypersensitivity to Voglibose or excipients
• Diabetic ketoacidosis, diabetic pre-coma
• Severe infection, serious trauma
• Gastrointestinal obstruction or predisposition to it

Side Effects

• Diarrhoea, loose stools, abdominal pain
• Constipation, nausea, vomiting
• Heartburn, increased gas, intestinal obstruction symptoms
• Hypoglycaemia with OHAs plus Vibose
• Fulminant hepatitis, serious liver dysfunction
• Numbness, edema, blurred vision
• Malaise, weakness, hyperkalemia, increased pancreatic enzyme

Pregnancy and Lactation

• Safety in pregnancy not established
• Exceedingly low levels in human milk
• Not recommended for nursing mothers

Precautions and Warnings

• Careful administration in patients receiving other antidiabetic drugs
• Caution in patients with laparotomy, ileus, chronic intestinal disease
• Special attention in patients with hepatic or renal dysfunction

Special Populations

• Poor absorption in renal failure
• No dose adjustment required in renal insufficiency

Overdose Effects

• Transient increase in flatulence, diarrhoea
• Abdominal discomfort, no hypoglycaemia risk

Therapeutic Class

• Alpha-Glucosidase inhibitor

Storage Conditions

• Cool and dry place
• Keep out of the reach of children
• Protect from light

Related Brands